Dyadic International, Inc, a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, has been issued US Patent No. 7,794,962 by the United States Patent and Trademark Office (USPTO).
The invention embodied by this patent provides a method for the expression and subsequent screening of DNA libraries in filamentous fungal hosts which may help speed up the discovery of novel genes and development of their corresponding enzymes and proteins.
This patent is the sixth US patent issued to Dyadic adding to its portfolio of 60 international patents and more than 40 pending patent applications worldwide which cover various features of Dyadic’s proprietary technologies.
Dyadic’s president and chief executive officer, Mark Emalfarb, stated, “As with our entire patent portfolio, we believe that this patent will help us further enhance our intellectual property protection of Dyadic’s cutting edge technologies, provide additional potential licensing opportunities and strengthen our competitive market position.”
Dyadic International is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries.